메뉴 건너뛰기




Volumn 6, Issue 7, 2011, Pages

Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: A meta-analysis

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

EID: 79960446259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022003     Document Type: Article
Times cited : (106)

References (61)
  • 1
    • 77954692660 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    • Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-33.
    • (2010) JAMA , vol.304 , pp. 321-333
    • Thompson, M.A.1    Aberg, J.A.2    Cahn, P.3    Montaner, J.S.4    Rizzardini, G.5
  • 2
    • 23044496716 scopus 로고    scopus 로고
    • Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study
    • Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, et al. (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366: 378-84.
    • (2005) Lancet , vol.366 , pp. 378-384
    • Sterne, J.A.1    Hernan, M.A.2    Ledergerber, B.3    Tilling, K.4    Weber, R.5
  • 3
    • 30944468562 scopus 로고    scopus 로고
    • Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    • Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-60.
    • (2006) N Engl J Med , vol.354 , pp. 251-260
    • Gallant, J.E.1    DeJesus, E.2    Arribas, J.R.3    Pozniak, A.L.4    Gazzard, B.5
  • 4
    • 27444444039 scopus 로고    scopus 로고
    • Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)
    • Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, et al. (2005) Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 40: 280-87.
    • (2005) J Acquir Immune Defic Syndr , vol.40 , pp. 280-287
    • Arribas, J.R.1    Pulido, F.2    Delgado, R.3    Lorenzo, A.4    Miralles, P.5
  • 5
    • 33845716442 scopus 로고    scopus 로고
    • A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy
    • Pierone G Jr, Mieras J, Bulgin-Coleman D, Kantor C, Shearer J, et al. (2006) A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials 7: 237-45.
    • (2006) HIV Clin Trials , vol.7 , pp. 237-245
    • Pierone Jr., G.1    Mieras, J.2    Bulgin-Coleman, D.3    Kantor, C.4    Shearer, J.5
  • 6
    • 77950957548 scopus 로고    scopus 로고
    • Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?
    • Battegay M, Bucher HC, (2010) Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy? AIDS 24: 1057-59.
    • (2010) AIDS , vol.24 , pp. 1057-1059
    • Battegay, M.1    Bucher, H.C.2
  • 7
    • 0344760902 scopus 로고    scopus 로고
    • Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
    • Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services
    • Panel on Antiretroviral Guidelines for Adults and Adolescents (2009) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
    • (2009)
  • 8
    • 78649382207 scopus 로고    scopus 로고
    • Clinical Management and Treatment of HIV Infected Adults in Europe
    • European AIDS Clinical Society, Accessed 2011 June 16
    • European AIDS Clinical Society (2009) Clinical Management and Treatment of HIV Infected Adults in Europe. http://www.europeanaidsclinicalsociety.org/guidelines.asp. Accessed 2011 June 16.
    • (2009)
  • 9
  • 11
    • 0037098199 scopus 로고    scopus 로고
    • Quantifying heterogeneity in a meta-analysis
    • Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-58.
    • (2002) Stat Med , vol.21 , pp. 1539-1558
    • Higgins, J.P.1    Thompson, S.G.2
  • 12
    • 0034823867 scopus 로고    scopus 로고
    • Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis
    • Sterne JA, Egger M, (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54: 1046-55.
    • (2001) J Clin Epidemiol , vol.54 , pp. 1046-1055
    • Sterne, J.A.1    Egger, M.2
  • 13
    • 78649775786 scopus 로고    scopus 로고
    • Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials
    • Soonawala D, Middelburg RA, Egger M, Vandenbroucke JP, Dekkers OM, (2010) Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. Int J Epidemiol 39: 1567-81.
    • (2010) Int J Epidemiol , vol.39 , pp. 1567-1581
    • Soonawala, D.1    Middelburg, R.A.2    Egger, M.3    Vandenbroucke, J.P.4    Dekkers, O.M.5
  • 14
    • 33644789375 scopus 로고    scopus 로고
    • Quality of reporting of noninferiority and equivalence randomized trials
    • Le HA, Giraudeau B, Baron G, Ravaud P, (2006) Quality of reporting of noninferiority and equivalence randomized trials. JAMA 295: 1147-51.
    • (2006) JAMA , vol.295 , pp. 1147-1151
    • Le, H.A.1    Giraudeau, B.2    Baron, G.3    Ravaud, P.4
  • 15
    • 0034077203 scopus 로고    scopus 로고
    • The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group
    • Gisolf EH, Jurriaans S, Pelgrom J, van Wanzeele F, van der Ende ME, et al. (2000) The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. AIDS 14: 405-13.
    • (2000) AIDS , vol.14 , pp. 405-413
    • Gisolf, E.H.1    Jurriaans, S.2    Pelgrom, J.3    van Wanzeele, F.4    van der Ende, M.E.5
  • 16
    • 0035870551 scopus 로고    scopus 로고
    • A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir
    • Eron JJ, Haubrich R, Lang W, Pagano G, Millard J, et al. (2001) A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. J Acquir Immune Defic Syndr 26: 458-61.
    • (2001) J Acquir Immune Defic Syndr , vol.26 , pp. 458-461
    • Eron, J.J.1    Haubrich, R.2    Lang, W.3    Pagano, G.4    Millard, J.5
  • 17
    • 0034457420 scopus 로고    scopus 로고
    • Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group
    • Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ, (2000) Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 31: 1234-39.
    • (2000) Clin Infect Dis , vol.31 , pp. 1234-1239
    • Gisolf, E.H.1    Dreezen, C.2    Danner, S.A.3    Weel, J.L.4    Weverling, G.J.5
  • 18
    • 38149028378 scopus 로고    scopus 로고
    • Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
    • Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, et al. (2008) Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 22: 385-93.
    • (2008) AIDS , vol.22 , pp. 385-393
    • Delfraissy, J.F.1    Flandre, P.2    Delaugerre, C.3    Ghosn, J.4    Horban, A.5
  • 19
    • 47649119335 scopus 로고    scopus 로고
    • A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy
    • Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, et al. (2008) A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 198: 234-40.
    • (2008) J Infect Dis , vol.198 , pp. 234-240
    • Cameron, D.W.1    da Silva, B.A.2    Arribas, J.R.3    Myers, R.A.4    Bellos, N.C.5
  • 20
    • 0032578860 scopus 로고    scopus 로고
    • Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team
    • Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, et al. (1998) Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 339: 1261-68.
    • (1998) N Engl J Med , vol.339 , pp. 1261-1268
    • Havlir, D.V.1    Marschner, I.C.2    Hirsch, M.S.3    Collier, A.C.4    Tebas, P.5
  • 21
    • 0034007440 scopus 로고    scopus 로고
    • Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3
    • Lewi DS, Suleiman JM, Uip DE, Pedro RJ, Souza RA, et al. (2000) Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3. Rev Inst Med Trop Sao Paulo 42: 27-36.
    • (2000) Rev Inst Med Trop Sao Paulo , vol.42 , pp. 27-36
    • Lewi, D.S.1    Suleiman, J.M.2    Uip, D.E.3    Pedro, R.J.4    Souza, R.A.5
  • 22
    • 0032883118 scopus 로고    scopus 로고
    • A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
    • Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, et al. (1999) A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 180: 659-665.
    • (1999) J Infect Dis , vol.180 , pp. 659-665
    • Hirsch, M.1    Steigbigel, R.2    Staszewski, S.3    Mellors, J.4    Scerpella, E.5
  • 23
    • 0032899327 scopus 로고    scopus 로고
    • Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
    • Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, et al. (1999) Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 179: 808-16.
    • (1999) J Infect Dis , vol.179 , pp. 808-816
    • Murphy, R.L.1    Gulick, R.M.2    DeGruttola, V.3    D'Aquila, R.T.4    Eron, J.J.5
  • 24
    • 79960469733 scopus 로고    scopus 로고
    • Boosted protease inhbitor monotherapy as maintenance second-line-retroviral therapy in Africa
    • July 18-23, 2010 Vienna Abstract LPBE16
    • Gilks CF, Walker AS, Munderi P, Reid A, Ssali F, et al. (2010) Boosted protease inhbitor monotherapy as maintenance second-line-retroviral therapy in Africa. XVIII Internationa AIDS Conference July 18-23, 2010 Vienna Abstract LPBE16.
    • (2010) XVIII Internationa AIDS Conference
    • Gilks, C.F.1    Walker, A.S.2    Munderi, P.3    Reid, A.4    Ssali, F.5
  • 29
    • 79960464997 scopus 로고    scopus 로고
    • Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure (BIDI-MONO) NCT01189695
    • Bamrasnaradura Infectious Diseases Institute
    • Bamrasnaradura Infectious Diseases Institute (2010) Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure (BIDI-MONO) NCT01189695.
    • (2010)
  • 32
    • 79960463195 scopus 로고    scopus 로고
    • Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs.Triple Therapy With a Boosted Protease Inhibitor (QoLKAMON) NCT01166477
    • Sociedad Andaluza de Enfermedades Infecciosas
    • Sociedad Andaluza de Enfermedades Infecciosas (2010) Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs.Triple Therapy With a Boosted Protease Inhibitor (QoLKAMON) NCT01166477.
    • (2010)
  • 33
    • 79960440282 scopus 로고    scopus 로고
    • Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy NCT00437476
    • IRCCS San Raffaele
    • IRCCS San Raffaele (2010) Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy NCT00437476.
    • (2010)
  • 35
    • 79960447410 scopus 로고    scopus 로고
    • A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy ISRCTN04857074
    • Medical Research Council Clinical Trials Unit LU
    • Medical Research Council Clinical Trials Unit LU (2010) A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy ISRCTN04857074.
    • (2010)
  • 36
    • 79960442621 scopus 로고    scopus 로고
    • The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1 infected patients: An unblinded, multicentre, randomised controlled trial ISRCTN04857074
    • Guy's & St.Thomas' NHS Foundation Trust (UK)
    • Guy's & St.Thomas' NHS Foundation Trust (UK) (2010) The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1 infected patients: An unblinded, multicentre, randomised controlled trial ISRCTN04857074.
    • (2010)
  • 37
    • 79960440282 scopus 로고    scopus 로고
    • Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy NCT00437684
    • IRCCS San Raffaele
    • IRCCS San Raffaele (2010) Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy NCT00437684.
    • (2010)
  • 38
    • 79960444501 scopus 로고    scopus 로고
    • HAART followed by maintenance with monotherapy - Kaletra (MAIMOKA) ISRCTN45284754
    • Vrije University Medical Centre (VUMC) (The Netherlands)
    • Vrije University Medical Centre (VUMC) (The Netherlands) (2010) HAART followed by maintenance with monotherapy- Kaletra (MAIMOKA) ISRCTN45284754.
    • (2010)
  • 40
    • 37549030881 scopus 로고    scopus 로고
    • Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
    • Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, et al. (2008) Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 22: F1-F9.
    • (2008) AIDS , vol.22 , pp. 1-9
    • Pulido, F.1    Arribas, J.R.2    Delgado, R.3    Cabrero, E.4    Gonzalez-Garcia, J.5
  • 41
    • 77957231616 scopus 로고    scopus 로고
    • Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir
    • Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, et al. (2010) Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24: 2347-54.
    • (2010) AIDS , vol.24 , pp. 2347-2354
    • Gutmann, C.1    Cusini, A.2    Gunthard, H.F.3    Fux, C.4    Hirschel, B.5
  • 42
    • 76749154576 scopus 로고    scopus 로고
    • Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study)
    • Nunes EP, Santini de OM, Mercon M, Zajdenverg R, Faulhaber JC, et al. (2009) Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials 10: 368-74.
    • (2009) HIV Clin Trials , vol.10 , pp. 368-374
    • Nunes, E.P.1    de Santini, O.M.2    Mercon, M.3    Zajdenverg, R.4    Faulhaber, J.C.5
  • 43
    • 79960460405 scopus 로고    scopus 로고
    • Efficacy and safety of lopinavir/ritonavir monotherapy vs. standard of care consisting of a protease inhibitor and two NRTIs in adults with HIV-1
    • 12th European AIDS Conference (EACS) November 11-14, 2009 Cologne, Germany Abstract P/S4 3
    • Cahn P, Andrade-Villanueva J, Sierra-Madero J, Casetti I, Junod P, et al. (2010) Efficacy and safety of lopinavir/ritonavir monotherapy vs. standard of care consisting of a protease inhibitor and two NRTIs in adults with HIV-1. 12th European AIDS Conference (EACS) November 11-14, 2009 Cologne, Germany Abstract P/S4 3.
    • (2010)
    • Cahn, P.1    Andrade-Villanueva, J.2    Sierra-Madero, J.3    Casetti, I.4    Junod, P.5
  • 44
    • 77957872525 scopus 로고    scopus 로고
    • Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: hte KALESOLO trial
    • Meynard JL, Bouteloup V, Landman R, Bonnard P, Baillat V, et al. (2010) Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: hte KALESOLO trial. J Antimicrob Chemother 65: 2436-44.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 2436-2444
    • Meynard, J.L.1    Bouteloup, V.2    Landman, R.3    Bonnard, P.4    Baillat, V.5
  • 45
    • 77957230936 scopus 로고    scopus 로고
    • Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136
    • Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, et al. (2010) Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 24: 2365-74.
    • (2010) AIDS , vol.24 , pp. 2365-2374
    • Katlama, C.1    Valantin, M.A.2    Algarte-Genin, M.3    Duvivier, C.4    Lambert-Niclot, S.5
  • 46
    • 74249086332 scopus 로고    scopus 로고
    • The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
    • Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, et al. (2010) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24: 223-30.
    • (2010) AIDS , vol.24 , pp. 223-230
    • Arribas, J.R.1    Horban, A.2    Gerstoft, J.3    Fatkenheuer, G.4    Nelson, M.5
  • 47
    • 78249266604 scopus 로고    scopus 로고
    • Saqinavir/ritonavir monotherapy as a new nucleoside sparing maintenance strategy in long-term virologically suppressed HIV-infected patients
    • Echeverria P, Domingo P, Gutierrez M, Mateo G, Fuster M, et al. (2010) Saqinavir/ritonavir monotherapy as a new nucleoside sparing maintenance strategy in long-term virologically suppressed HIV-infected patients. Curr HIV Res 8: 467-70.
    • (2010) Curr HIV Res , vol.8 , pp. 467-470
    • Echeverria, P.1    Domingo, P.2    Gutierrez, M.3    Mateo, G.4    Fuster, M.5
  • 48
    • 79960455994 scopus 로고    scopus 로고
    • Lopinavir/ritonavir as single-drug for maintenance of HIV-1 viral suppression. A randomized, controlled, open label, pilot, clinical trial (OK Study): 72 weeks analysis
    • 10th European AIDS Conference/EACS, November 17-20, 2005 Dublin, Irleand Abstract PE7 5/5
    • Pulido F, Arribas J, Delgado R, Pano JR, Lorenzo A, et al. (2010) Lopinavir/ritonavir as single-drug for maintenance of HIV-1 viral suppression. A randomized, controlled, open label, pilot, clinical trial (OK Study): 72 weeks analysis. 10th European AIDS Conference/EACS, November 17-20, 2005 Dublin, Irleand Abstract PE7 5/5.
    • (2010)
    • Pulido, F.1    Arribas, J.2    Delgado, R.3    Pano, J.R.4    Lorenzo, A.5
  • 49
    • 67649207695 scopus 로고    scopus 로고
    • Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
    • Arribas JR, Delgado R, Arranz A, Munoz R, Portilla J, et al. (2009) Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 51: 147-52.
    • (2009) J Acquir Immune Defic Syndr , vol.51 , pp. 147-152
    • Arribas, J.R.1    Delgado, R.2    Arranz, A.3    Munoz, R.4    Portilla, J.5
  • 50
    • 79960438105 scopus 로고    scopus 로고
    • The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r +2NRTIs, for patients with HIV RNA <50 copies/mL at baseline
    • XVIII Internationa AIDS Conference, July 18-23, 2010 Vienna, Austria Abstract TBLBB209
    • Rieger A, Banhegyi D, Schmidt W, Arribas J, Hill A, et al. (2010) The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r +2NRTIs, for patients with HIV RNA <50 copies/mL at baseline. XVIII Internationa AIDS Conference, July 18-23, 2010 Vienna, Austria Abstract TBLBB209.
    • (2010)
    • Rieger, A.1    Banhegyi, D.2    Schmidt, W.3    Arribas, J.4    Hill, A.5
  • 51
    • 0029987569 scopus 로고    scopus 로고
    • Trials to assess equivalence: the importance of rigorous methods
    • Jones B, Jarvis P, Lewis JA, Ebbutt AF, (1996) Trials to assess equivalence: the importance of rigorous methods. BMJ 313: 36-39.
    • (1996) BMJ , vol.313 , pp. 36-39
    • Jones, B.1    Jarvis, P.2    Lewis, J.A.3    Ebbutt, A.F.4
  • 52
    • 38949173080 scopus 로고    scopus 로고
    • Current issues in non-inferiority trials
    • Fleming TR, (2008) Current issues in non-inferiority trials. Stat Med 27: 317-32.
    • (2008) Stat Med , vol.27 , pp. 317-332
    • Fleming, T.R.1
  • 53
    • 77954882772 scopus 로고    scopus 로고
    • U.S.Department of Health and Human Services Food and Drug Administration,. Accessed 2011 June 16
    • U.S.Department of Health and Human Services Food and Drug Administration (2010) Guidance for Industry, Non-inferiority Clinical Trials. http://www.fda.gov/../GuidanceComplianceRegulatoryInformation/Guidances/ucm202140.pdf. Accessed 2011 June 16.
    • (2010) Guidance for Industry, Non-inferiority Clinical Trials
  • 54
    • 43649090700 scopus 로고    scopus 로고
    • Designing and interpreting HIV noninferiority trials in naive and experienced patients
    • Hill A, Sabin C, (2008) Designing and interpreting HIV noninferiority trials in naive and experienced patients. AIDS 22: 913-21.
    • (2008) AIDS , vol.22 , pp. 913-921
    • Hill, A.1    Sabin, C.2
  • 55
    • 76749136667 scopus 로고    scopus 로고
    • Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy
    • Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, et al. (2010) Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50: 773-78.
    • (2010) Clin Infect Dis , vol.50 , pp. 773-778
    • Canestri, A.1    Lescure, F.X.2    Jaureguiberry, S.3    Moulignier, A.4    Amiel, C.5
  • 56
    • 47649119335 scopus 로고    scopus 로고
    • A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy
    • Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, et al. (2008) A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 198: 234-40.
    • (2008) J Infect Dis , vol.198 , pp. 234-240
    • Cameron, D.W.1    da Silva, B.A.2    Arribas, J.R.3    Myers, R.A.4    Bellos, N.C.5
  • 57
    • 79960464057 scopus 로고    scopus 로고
    • Fat tissue distribution changes in HIV-infected patients with viral suppression treated with DRV/r monotherapy vs 2 NRTI + DRV/r in the MONO-ANRS 136 randomized trial: Results at 48 weeks
    • 17th Conerence on Retroviruses and Opportunistic Infections, February 16-19,2010, San Franciso, USA Abstract 721
    • Valantin MA, Flandre P, Kolta S, Duvivier C, Algarte-Genin M, et al. (2010) Fat tissue distribution changes in HIV-infected patients with viral suppression treated with DRV/r monotherapy vs 2 NRTI + DRV/r in the MONO-ANRS 136 randomized trial: Results at 48 weeks. 17th Conerence on Retroviruses and Opportunistic Infections, February 16-19,2010, San Franciso, USA Abstract 721.
    • (2010)
    • Valantin, M.A.1    Flandre, P.2    Kolta, S.3    Duvivier, C.4    Algarte-Genin, M.5
  • 58
    • 68449093191 scopus 로고    scopus 로고
    • First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir
    • van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, et al. (2009) First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 23: 1367-76.
    • (2009) AIDS , vol.23 , pp. 1367-1376
    • van Vonderen, M.G.1    Lips, P.2    van Agtmael, M.A.3    Hassink, E.A.4    Brinkman, K.5
  • 59
    • 79551583044 scopus 로고    scopus 로고
    • Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial
    • Hansen A, Obel N, Nielsen H, Pedersen C, Gerstoft J, (2010) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 12: 157-65.
    • (2010) HIV Med , vol.12 , pp. 157-165
    • Hansen, A.1    Obel, N.2    Nielsen, H.3    Pedersen, C.4    Gerstoft, J.5
  • 60
    • 34848824668 scopus 로고    scopus 로고
    • Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial
    • Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, et al. (2007) Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 45: 1062-70.
    • (2007) Clin Infect Dis , vol.45 , pp. 1062-1070
    • Schackman, B.R.1    Scott, C.A.2    Sax, P.E.3    Losina, E.4    Wilkin, T.J.5
  • 61
    • 79960440111 scopus 로고    scopus 로고
    • Cost effectiveness of switching to second line therapy with lopinavir/ritonavir (LPV/r) in Kenya and Uganda
    • 5th International AIDS Society Conference on Pathogenesis, Treatment and Prevention, July 19-22, 2009, Cape Town, South Africa Abstract MOPED012
    • Simpson KN, Dietz B, Rahim B, S.Rayagopalan R, (2009) Cost effectiveness of switching to second line therapy with lopinavir/ritonavir (LPV/r) in Kenya and Uganda. 5th International AIDS Society Conference on Pathogenesis, Treatment and Prevention, July 19-22, 2009, Cape Town, South Africa Abstract MOPED012.
    • (2009)
    • Simpson, K.N.1    Dietz, B.2    Rahim, B.3    Rayagopalan, S.R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.